Rotterdam

• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Recruiting
  2023-507460-39-00 10 2024-02-15 Adult patients with resectable muscle-invasive urothelial cancer of th
• PREMI trial Recruiting
  2023-503220-76-01 6 2024-02-13 Unexplained recurrent miscarriages
• Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting
  2023-504146-60-00 10 2024-02-07 lymphatic malformations associated with PIK3CA mutation
• Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol … Recruiting
  2023-506698-36-00 5 2024-02-02 low-volume metastatic castration-sensitive prostate cancer
• Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting
  2023-503327-26-00 5 2024-01-31 Sjogren's syndrome
• Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress Recruiting
  2023-509142-35-00 6 2024-01-29 Atrial fibrillation after stress (e.g., noncardiac surgery or acute me
• A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emis … Recruiting
  2023-506971-89-00 5 2024-01-25 Coronary Artery Disease
• Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal ad … Recruiting
  2024-514597-42-00 9 2024-01-16 Metastatic pancreatic cancer
• PEHAB II Recruiting
  2023-507466-40-00 6 2024-01-12 Prostate cancer
• STEPS-EA trial Recruiting
  2023-504905-36-00 11 2024-01-11 Strictures after esophageal atresia repair
• A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting
  2023-504807-94-00 7 2023-12-26 Breast Cancer; Advanced solid tumors including but not limited to gyne
• Neo-adjuvant pembroliuzmab as an alternative treatment for MMRd uterine cancer Recruiting
  2024-516736-10-00 4 2023-12-18 Mismatch repair deficient endometrial cancer / uterine cancer
• A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma Recruiting
  2022-502984-39-00 5 2023-12-13 Severe Uncontrolled Asthma Asthma (an illness that causes breathing di
• An Extension study of the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Participants With Mucopolysaccharidosis Type II (MPS II) … Recruiting
  2023-503837-23-00 5 2023-12-12 Mucopolysaccharidosis Type II [MPS II]
• Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting
  2022-501997-20-00 7 2023-12-01 participants with isolated methylmalonic acidemia (MMA) due to methylm
• ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer Recruiting
  2023-503533-21-00 4 2023-11-21 Low-grade serous ovarian cancer
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: … Recruiting
  2023-503558-10-00 5 2023-10-13 oligometastatic pancreatic cancer
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting
  2023-510541-25-00 1 2023-10-09 Relapsed/Refractory B-cell Malignancies
• Treatment of Menière's disease with intratympanic methylprednisolone (PREDMEN trial) Recruiting
  2023-503340-13-00 5 2023-10-05 Menière's disease
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Subjects 1 Year of Age and Older Recruiting
  2022-503081-74-00 5 2023-09-05 Cystic Fibrosis
• A Phase 1 study of LOXO-435 in Locally Advanced or Metastatic Solid Tumors with FGFR3 Gene Alterations Recruiting
  2022-502755-59-00 1 2023-08-30 Locally Advanced or Metastatic Solid Tumors with FGFR3 Alterations

Showing 361–384 of 818 trials